biote Corp.

BTMD ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021
Revenue $192.2M $197.2M $185.4M $165.0M $139.4M
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development
SG&A Expense $101.8M $107.5M $98.8M $171.1M $49.1M
Operating Income $35.6M $31.6M $28.7M $-60.7M $34.6M
Operating Margin 18.5% 16.0% 15.5% -36.8% 24.8%
Interest Expense
Pretax Income $37.6M $1.0M $-123.0K $1.7M $32.9M
Income Tax Expense $6.0M $970.0K $2.7M $388.0K $286.0K
Net Income $27.0M $3.2M $3.3M $-969.0K $11.1M
Net Margin 14.1% 1.6% 1.8% -0.6% 8.0%
EPS (Basic) $0.86 $0.09 $0.13 $-0.04
EPS (Diluted) $0.74 $0.09 $0.13 $-0.04
Shares Outstanding (Basic) 31.3M 34.3M 25.7M 24.2M
Shares Outstanding (Diluted) 36.7M 34.3M 25.7M 24.2M
Dividends Per Share